Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Programmed Cell Death 1 Receptor. Found 7 abstracts

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulieres D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. The New England journal of medicine. 2019 Mar 21;380(12):1116-27.
Gerson JN, Ramamurthy C, Borghaei H. Managing adverse effects of immunotherapy. Clinical advances in hematology & oncology : H&O. 2018 May;16(5):364-74.   PMCID: Review
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RH, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017 Sep 07;170(6):1109-1119e10.
Sznol M, Postow MA, Davies MJ, Pavlick AC, Plimack ER, Shaheen M, Veloski C, Robert C. Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. Cancer Treat Rev. 2017 Jul;58:70-6.   PMCID: Review
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. The New England journal of medicine. 2015 Jan 22;372(4):311-9.   PMCID: 4348009
Godwin JL, Zibelman M, Plimack ER, Geynisman DM. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. Discov Med. 2014 Dec;18(101):341-50.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Programmed Cell Death 1 Receptor

Programmed Cell Death 1 Receptor antagonists & inhibitors drug therapy adverse effects Monoclonal Antibodies Immunotherapy Monoclonal Antibodies-Humanized CTLA-4 Antigen Antineoplastic Agents administration & dosage therapy immunology therapeutic use Melanoma Male Middle Aged genetics Adult Female pathology B7-H1 Antigen Ipilimumab Kidney Neoplasms Renal Cell Carcinoma oncolytic immunotherapy metabolism Janus Kinases Colitis diagnosis Non-muscle-invasive Herpesviridae chemically induced Sunitinib CD274 Antigens etiology physiology Checkpoint inhibitor Intention to Treat Analysis Pneumonia ctla-4 Muscle-invasive Preclinical Drug Evaluation drug effects tumor epidemiology Progression-Free Survival oncolytic viruses Dermatitis Reed-Sternberg Cells Combined Modality Therapy interferon gamma anti-PD-1 methods Single-Blind Method cytotixic Neoplastic Gene Expression Regulation Neoplasms Oncolytic Virotherapy Urinary Bladder Neoplasms Thyroiditis Retrospective Studies STAT Transcription Factors pembrolizumab Therapy talimogene laherparepvec Tumor Microenvironment Stem Cell Transplantation Protein Kinase Inhibitors Antineoplastic Combined Chemotherapy Protocols Hodgkin Disease Programmed Cell Death 1 Ligand 2 Protein Hepatitis Immune-related adverse events Treatment Endocrine System Diseases biomarkers 80 and over Aged Immunological Antineoplastic Agents melanoma Bladder cancer Transitional Cell Carcinoma pd-1 Cell Cycle Checkpoints Aged T lymphocytes Disease Management Nivolumab Axitinib Recurrence Survival Rate Immunoconjugates mortality Clinical Trials as Topic Intravenous Administration pd-l1 Localized Hypophysitis Hematologic Neoplasms prevention & control
Last updated on Friday, August 14, 2020